ClinicalTrials.gg
CompletedNCT05174065Updated Apr 9, 2025Results posted

Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)

A Phase 3 interventional study of Apremilast and Placebo in Palmoplantar Pustulosis, sponsored by Amgen. Completed at 40 sites in Japan. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
17th of 44
176 · median 103
Started
2022
with 1 other
Phase 3
18 of 44
none open now
Registered
35th of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 17th largest by enrollment, is one of 2 that started in 2022, is one of 18 in phase 3, and was the 35th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).

03

Conditions studied

  • Palmoplantar Pustulosis

Browse trials for

Keywords

  • Palmoplantar Pustulosis
  • PPP
  • AMG 407
  • Apremilast
  • Otezla
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Key Inclusion Criteria

    • Japanese participants ≥ 18 years of age upon entry into initial screening
    • Palmoplantar pustulosis diagnosis with or without pustulotic arthro-osteitis (PAO) for no less than 24 weeks
    • PPPASI total score of ≥12 at screening and at baseline
    • Moderate or severe pustules/vesicles on palms or soles (PPPASI severity score ≥2) at screening and at baseline
    • Inadequate response (defined as repeated relapsing-remitting in the same location for a 24-week period) to topical treatments prior to or at screening
  • Key Exclusion Criteria

    • Changes in disease severity during screening (PPPASI total score change ≥ 5 improvement, from screening to baseline)
    • Periodontitis requiring treatment
    • Chronic or recurrent tonsillitis or sinusitis requiring any continuous treatment
    • Has a diagnosis of plaque-type psoriasis at baseline
    • Has the presence of pustular psoriasis on any part of the body other than the palms and soles
    • Has evidence of skin conditions of hand and feet at baseline that would interfere with evaluations of the effect of Product
    • Has unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within 12 weeks prior to screening
    • or history of malignancy
    • Participant has received any procedures for focal infection within 24 weeks of baseline
    • Female participants who are breastfeeding or who plan to breastfeed while on study
    • Female participants of with a positive pregnancy test
    • Had prior treatment with apremilast
    • Has a prior medical history of suicide attempt at any time in the participant's lifetime prior to signing of or randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing of informed consent
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Apremilast

    Apremilast will be administered to participants twice daily (BID)

    Drug: Apremilast

  • Experimental
    Placebo and Apremilast

    Matching placebo will be administered to participants twice daily (BID) until week 16. After week 16, Apremilast will be administered to participants BID.

    Drug: Apremilast · Drug: Placebo

Interventions

  • Oral tablets

    Also known as: Otezla, AMG 407

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at Week 16

    A PPPASI 50 response is defined as a ≥ 50% reduction in PPPASI total score from baseline. The PPPASI is a system used for assessing and grading the severity (in terms of erythema, pustules/vesicle and desquamation/scale) and area of PPP lesions and their response to therapy. The PPPASI produces a numeric score that can range from 0 to 72, with a higher score indicating more severe disease. Participants who discontinued investigational product before week 16 due to lack of efficacy, adverse event, or use of protocol-prohibited medication (intercurrent events) were to be considered as treatment failures as the result of the intercurrent event and the PPPASI-50 values for visits on and after the intercurrent event were imputed as non-responders. The missing PPPASI-50 values due to the other reasons were imputed using the multiple imputation method.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Change From Baseline in PPPASI Total Score at Week 16

    The PPPASI is a system used for assessing and grading the severity (in terms of erythema, pustules/vesicle and desquamation/scale) and area of PPP lesions and their response to therapy. The PPPASI produces a numeric score that can range from 0 to 72, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of intercurrent event (IE) (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the mixed-effects model for repeated measures (MMRM) application.

    Time frame: Baseline and Week 16

  2. Change From Baseline in Palmoplantar Pustulosis Severity Index (PPSI) Total Score at Week 16

    The PPSI is a system used for assessing and grading the severity of PPP lesions and their response to therapy. Evaluation of skin lesion site are assessed separately for erythema, pustules/vesicle and desquamation/scale, where each are rated on a scale of 0 to 4 and summed to produce a numeric total score than can range from 0 to 12, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.

    Time frame: Baseline and Week 16

  3. Change From Baseline in Visual Analogue Scale (VAS) Assessment for PPP Symptoms (Pruritus) at Week 16

    Participants assessed the degree of pruritus itching symptoms on palms and soles caused by PPP on a VAS. The VAS score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no itch and the right-hand boundary (100) represents itch as severe as can be imagined by the participant. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.

    Time frame: Baseline and Week 16

  4. Change From Baseline in VAS Assessment for PPP Symptoms (Pain/Discomfort) at Week 16

    Participants assessed the degree of pain/discomfort symptoms on palms and soles caused by PPP on a VAS. The VAS score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no pain/discomfort and the right-hand boundary (100) represents pain/discomfort as severe as can be imagined by the participant. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.

    Time frame: Baseline and Week 16

  5. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16

    The DLQI is a skin disease-specific Quality of Life (QoL) questionnaire comprised of 10 items assessing the participant's status over the previous week. The DLQI was used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The DLQI produces a numeric score ranging from 0 to 30, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.

    Time frame: Baseline and Week 16

  6. Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

    TEAEs were defined as any untoward medical occurrence in a participant irrespective of a causal relationship with the study treatment that began or worsened on or after the first dose of study treatment. A serious TEAE met at least 1 of the following criteria: * Resulted in death. * Was immediately life-threatening. * Required in-patient hospitalization or prolongation of existing hospitalization. * Resulted in persistent or significant disability/incapacity. * Was a congenital anomaly/birth defect. * Was any other medically important serious event. TEAEs of interest were defined as any of the following: * Depression. * Serious infection. * Risk of triggering suicide. * Serious diarrhea, nausea and vomiting. * Malignancies. * Vasculitis and Vasculopathy. * Serious Hypersensitivity. * Weight change (weight decrease). Clinically significant changes in body weight, vital signs and laboratory abnormalities were also recorded as TEAEs.

    Time frame: Placebo-controlled period: Day 1 to Week 16; Apremilast exposure period : Apremilast Day 1 to a maximum of Week 52 (plus 4 weeks safety follow-up)

07

Results

Posted Apr 9, 2025

Participant flow

Participants with palmoplantar pustulosis (PPP) took part in the study at 40 centers in Japan between 08 March 2022 and 01 June 2024.

Placebo-controlled Period
Participant flow — Placebo-controlled Period
MilestonePlacebo-controlled Period: PlaceboPlacebo-controlled Period: ApremilastActive Treatment Period: Apremilast
Started88880
Received apremilast or placebo during placebo-controlled period88880
Completed86860
Not completed220
Withdrew: Withdrawal by subject100
Withdrew: Other010
Withdrew: Adverse event110
Apremilast Active Treatment Period
Participant flow — Apremilast Active Treatment Period
MilestonePlacebo-controlled Period: PlaceboPlacebo-controlled Period: ApremilastActive Treatment Period: Apremilast
Started00172
Received apremilast during the active treatment period00172
Completed00164
Not completed008
Withdrew: Withdrawal by subject003
Withdrew: Protocol violation001
Withdrew: Adverse event004

Outcome measures

PrimaryPercentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at Week 16

A PPPASI 50 response is defined as a ≥ 50% reduction in PPPASI total score from baseline. The PPPASI is a system used for assessing and grading the severity (in terms of erythema, pustules/vesicle and desquamation/scale) and area of PPP lesions and their response to therapy. The PPPASI produces a numeric score that can range from 0 to 72, with a higher score indicating more severe disease. Participants who discontinued investigational product before week 16 due to lack of efficacy, adverse event, or use of protocol-prohibited medication (intercurrent events) were to be considered as treatment failures as the result of the intercurrent event and the PPPASI-50 values for visits on and after the intercurrent event were imputed as non-responders. The missing PPPASI-50 values due to the other reasons were imputed using the multiple imputation method.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at Week 16
percentage of participantsPlacebo-controlled Period: PlaceboPlacebo-controlled Period: Apremilast
Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at Week 1635.3 (25.3 to 45.4)67.8 (57.9 to 77.6)
Statistical analysis
  • Placebo-controlled Period: Placebo vs Placebo-controlled Period: Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference in proportion: 32.6 · 95% CI 18.7 to 46.5Based on the Cochran-Mantel-Haenszel method adjusting for the stratification factors. The adjusted difference in proportion was the weighted average of the treatment differences across strata.
SecondaryChange From Baseline in PPPASI Total Score at Week 16

The PPPASI is a system used for assessing and grading the severity (in terms of erythema, pustules/vesicle and desquamation/scale) and area of PPP lesions and their response to therapy. The PPPASI produces a numeric score that can range from 0 to 72, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of intercurrent event (IE) (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the mixed-effects model for repeated measures (MMRM) application.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in PPPASI Total Score at Week 16
score on a scalePlacebo-controlled Period: PlaceboPlacebo-controlled Period: Apremilast
Change From Baseline in PPPASI Total Score at Week 16-5.98 ± 0.999-12.12 ± 1.002
Statistical analysis
  • Placebo-controlled Period: Placebo vs Placebo-controlled Period: Apremilast · MMRM · p = <0.0001 · Difference in least squares mean: -6.13 · 95% CI -8.57 to -3.69Apremilast - Placebo
SecondaryChange From Baseline in Palmoplantar Pustulosis Severity Index (PPSI) Total Score at Week 16

The PPSI is a system used for assessing and grading the severity of PPP lesions and their response to therapy. Evaluation of skin lesion site are assessed separately for erythema, pustules/vesicle and desquamation/scale, where each are rated on a scale of 0 to 4 and summed to produce a numeric total score than can range from 0 to 12, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Palmoplantar Pustulosis Severity Index (PPSI) Total Score at Week 16
score on a scalePlacebo-controlled Period: PlaceboPlacebo-controlled Period: Apremilast
Change From Baseline in Palmoplantar Pustulosis Severity Index (PPSI) Total Score at Week 16-1.9 ± 0.24-3.4 ± 0.24
Statistical analysis
  • Placebo-controlled Period: Placebo vs Placebo-controlled Period: Apremilast · MMRM · p = <0.0001 · Difference in least squares mean: -1.5 · 95% CI -2.2 to -0.9Apremilast - Placebo
SecondaryChange From Baseline in Visual Analogue Scale (VAS) Assessment for PPP Symptoms (Pruritus) at Week 16

Participants assessed the degree of pruritus itching symptoms on palms and soles caused by PPP on a VAS. The VAS score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no itch and the right-hand boundary (100) represents itch as severe as can be imagined by the participant. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Visual Analogue Scale (VAS) Assessment for PPP Symptoms (Pruritus) at Week 16
score on a scalePlacebo-controlled Period: PlaceboPlacebo-controlled Period: Apremilast
Change From Baseline in Visual Analogue Scale (VAS) Assessment for PPP Symptoms (Pruritus) at Week 16-9.9 ± 2.68-17.6 ± 2.67
Statistical analysis
  • Placebo-controlled Period: Placebo vs Placebo-controlled Period: Apremilast · MMRM · p = 0.0330 · Difference in least squares mean: -7.8 · 95% CI -14.9 to -0.6Apremilast - Placebo
SecondaryChange From Baseline in VAS Assessment for PPP Symptoms (Pain/Discomfort) at Week 16

Participants assessed the degree of pain/discomfort symptoms on palms and soles caused by PPP on a VAS. The VAS score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no pain/discomfort and the right-hand boundary (100) represents pain/discomfort as severe as can be imagined by the participant. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in VAS Assessment for PPP Symptoms (Pain/Discomfort) at Week 16
score on a scalePlacebo-controlled Period: PlaceboPlacebo-controlled Period: Apremilast
Change From Baseline in VAS Assessment for PPP Symptoms (Pain/Discomfort) at Week 16-7.5 ± 2.97-18.3 ± 2.96
Statistical analysis
  • Placebo-controlled Period: Placebo vs Placebo-controlled Period: Apremilast · MMRM · p = 0.0076 · Difference in least squares mean: -10.8 · 95% CI -18.6 to -2.9Apremilast - Placebo
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16

The DLQI is a skin disease-specific Quality of Life (QoL) questionnaire comprised of 10 items assessing the participant's status over the previous week. The DLQI was used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The DLQI produces a numeric score ranging from 0 to 30, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
score on a scalePlacebo-controlled Period: PlaceboPlacebo-controlled Period: Apremilast
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16-0.8 ± 0.37-2.3 ± 0.37
Statistical analysis
  • Placebo-controlled Period: Placebo vs Placebo-controlled Period: Apremilast · MMRM · p = 0.0036 · Difference in least squares mean: -1.4 · 95% CI -2.4 to -0.5Apremilast - Placebo
SecondaryNumber of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

TEAEs were defined as any untoward medical occurrence in a participant irrespective of a causal relationship with the study treatment that began or worsened on or after the first dose of study treatment. A serious TEAE met at least 1 of the following criteria: * Resulted in death. * Was immediately life-threatening. * Required in-patient hospitalization or prolongation of existing hospitalization. * Resulted in persistent or significant disability/incapacity. * Was a congenital anomaly/birth defect. * Was any other medically important serious event. TEAEs of interest were defined as any of the following: * Depression. * Serious infection. * Risk of triggering suicide. * Serious diarrhea, nausea and vomiting. * Malignancies. * Vasculitis and Vasculopathy. * Serious Hypersensitivity. * Weight change (weight decrease). Clinically significant changes in body weight, vital signs and laboratory abnormalities were also recorded as TEAEs.

Time frame:
Placebo-controlled period: Day 1 to Week 16; Apremilast exposure period : Apremilast Day 1 to a maximum of Week 52 (plus 4 weeks safety follow-up)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
ParticipantsPlacebo-controlled Period: PlaceboPlacebo-controlled Period: ApremilastApremilast Exposure Period: Apremilast
Any TEAEs4363148
Serious TEAEs119
TEAEs of Interest318

Adverse events

Collected over Placebo-controlled period: Day 1 to Week 16; Apremilast exposure period : Apremilast Day 1 to a maximum of Week 52 (plus 4 weeks safety follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-controlled Period: Placebo0/88 (0%)1/88 (1.1%)25/88 (28.4%)
Placebo-controlled Period: Apremilast0/88 (0%)1/88 (1.1%)46/88 (52.3%)
Apremilast Exposure Period: Apremilast0/174 (0%)9/174 (5.2%)99/174 (56.9%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlacebo-controlled Period: PlaceboPlacebo-controlled Period: ApremilastApremilast Exposure Period: Apremilast
CataractEye disorders0/880/882/174
Acute myocardial infarctionCardiac disorders1/880/880/174
Pseudoaneurysm infectionInfections and infestations1/880/880/174
Cerebellar haemorrhageNervous system disorders0/881/881/174
Duodenal perforationGastrointestinal disorders0/880/881/174
CholelithiasisHepatobiliary disorders0/880/881/174
PyelonephritisInfections and infestations0/880/881/174
Pyelonephritis acuteInfections and infestations0/880/881/174
Viral infectionInfections and infestations0/880/881/174
OsteoarthritisMusculoskeletal and connective tissue disorders0/880/881/174
Most frequent other events
Most frequent other events
EventPlacebo-controlled Period: PlaceboPlacebo-controlled Period: ApremilastApremilast Exposure Period: Apremilast
DiarrhoeaGastrointestinal disorders3/8817/8831/174
Faeces softGastrointestinal disorders1/8815/8822/174
NasopharyngitisInfections and infestations8/884/8828/174
NauseaGastrointestinal disorders1/8810/8823/174
HeadacheNervous system disorders2/8810/8819/174
COVID-19Infections and infestations4/884/8818/174
Palmoplantar pustulosisSkin and subcutaneous tissue disorders5/884/8812/174
EczemaSkin and subcutaneous tissue disorders3/885/8811/174
Back painMusculoskeletal and connective tissue disorders5/880/885/174

Baseline characteristics

Intent-to-treat Population: Included all randomized participants (i.e., participants who entered the placebo-controlled period).

Age, Continuous
Age, Continuous(years)Placebo-controlled Period: PlaceboPlacebo-controlled Period: ApremilastTotal
Mean56.0 ± 11.3557.0 ± 11.3256.5 ± 11.32
Sex: Female, Male
Sex: Female, Male(Participants)Placebo-controlled Period: PlaceboPlacebo-controlled Period: ApremilastTotal
Female7269141
Male161935
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo-controlled Period: PlaceboPlacebo-controlled Period: ApremilastTotal
Hispanic or Latino000
Not Hispanic or Latino8888176
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo-controlled Period: PlaceboPlacebo-controlled Period: ApremilastTotal
Asian8888176
08

Study locations

40 sites
  • Aichi Medical University Hospital
    Nagakute-shi, Aichi-ken 480-1195, Japan
  • Nagoya City University Hospital
    Nagoya, Aichi-ken 467-8602, Japan
  • Toho University Sakura Medical Center
    Sakura-shi, Chiba 285-8741, Japan
  • Ehime University Hospital
    Toon-shi, Ehime 791-0295, Japan
  • Kusuhara Dermatology Clinic
    Fukuoka, Fukuoka 811-1302, Japan
  • Fukuoka University Hospital
    Fukuoka, Fukuoka 814-0180, Japan
  • Higuchi Dermatology Urology Clinic
    Kasuga-shi, Fukuoka 816-0802, Japan
  • Kurume University Hospital
    Kurume-shi, Fukuoka 830-0011, Japan
  • Nagata Dermatology Clinic
    Ogori-shi, Fukuoka 838-0144, Japan
  • Fukushima Medical University Hospital
    Fukushima, Fukushima 960-1295, Japan
  • Central Japan International Medical Center
    Minokamo-shi, Gifu 505-8510, Japan
  • Motomachi Dermatology Clinic
    Asahikawa-shi, Hokkaido 070-0810, Japan
  • Asahikawa Medical University Hospital
    Asahikawa-shi, Hokkaido 078-8510, Japan
  • Medical corporation kojinkai Chitose dermatology and plastic surgery clinic
    Chitose-shi, Hokkaido 066-0021, Japan
  • Shinoro Dermatology Clinic
    Sapporo, Hokkaido 002-8022, Japan
  • Medical Corporation Kojinkai Kitago Dermatology Clinic
    Sapporo, Hokkaido 003-0833, Japan
  • Shibaki Dermatology Clinic
    Sapporo, Hokkaido 006-0022, Japan
  • Medical Corporation Kojinkai Sapporo Skin Clinic
    Sapporo, Hokkaido 060-0063, Japan
  • Kobe University Hospital
    Kobe, Hyōgo 650-0017, Japan
  • Mito Kyodo General Hospital
    Mito, Ibaraki 310-0015, Japan
  • Ishikawa Prefectural Central Hospital
    Kanazawa, Ishikawa-ken 920-8530, Japan
  • Takamatsu Red Cross Hospital
    Takamatsu, Kagawa-ken 760-0017, Japan
  • Kagoshima University Hospital
    Kagoshima, Kagoshima-ken 890-8520, Japan
  • Nomura Dermatology Clinic
    Yokohama, Kanagawa 221-0825, Japan
  • Kochi Medical School Hospital
    Nankoku-shi, Kochi 783-8505, Japan
  • Nagaoka Red Cross Hospital
    Nagaoka-shi, Niigata 940-2085, Japan
  • Oita University Hospital
    Yufu-shi, Oita Prefecture 879-5593, Japan
  • Nippon Life Hospital
    Osaka, Osaka 550-0006, Japan
  • Medical Corporation Goto Dermatology Clinic
    Osaka, Osaka 554-0021, Japan
  • Dermatology and Ophthalmology Kume Clinic
    Sakai-shi, Osaka 593-8324, Japan
  • Yoshikawa Skin Clinic
    Takatsuki-shi, Osaka 569-0824, Japan
  • Dokkyo Medical University Saitama Medical Center
    Koshigaya-shi, Saitama 343-8555, Japan
  • Pansy Skin Clinic
    Saitama-shi, Saitama 330-0064, Japan
  • Jichi Medical University Hospital
    Shimotsuke-shi, Tochigi 329-0498, Japan
  • Tokyo Teishin Hospital
    Chiyoda-ku, Tokyo 102-8798, Japan
  • Teikyo University Hospital
    Itabashi-ku, Tokyo 173-8606, Japan
  • Nihon University Itabashi Hospital
    Itabashi-ku, Tokyo 173-8610, Japan
  • Tokyo Medical University Hospital
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Seibo International Catholic Hospital
    Shinjuku-ku, Tokyo 161-8521, Japan
  • Yamanashi Prefectural Central Hospital
    Kofu, Yamanashi 400-8506, Japan
09

References and documents

Publications

  • Terui T, Okubo Y, Kobayashi S, Morita A, Imafuku S, Tada Y, Abe M, Strober B, Gooderham M, Zhang W, Shimauchi J, Yaguchi M, Kimura T, Ogawa R, Amouzadeh H, Murakami M. Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial. J Eur Acad Dermatol Venereol. 2026 Jun;40(6):994-1004. doi: 10.1111/jdv.70166. Epub 2025 Nov 26. PubMed 41297955 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Aug 2023, 17 months.

Results were first posted in Apr 2025, 1 year 7 months after primary completion. A results delay was requested in Apr 2024.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 17 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2021
First posted
Dec 30, 2021
StartActual
Mar 8, 2022
Primary completionActual
Aug 19, 2023
CompletionActual
Jun 1, 2024
Results delay requested
Apr 19, 2024
Results first posted
Apr 9, 2025
Last update
Apr 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05174065
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 30, 2021
Start date
Mar 8, 2022
Primary completion
Aug 19, 2023
Completion
Jun 1, 2024
Results posted
Apr 9, 2025
Last update
Apr 9, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion